To estimate the expected change in serum lipoprotein concentrations after treatment with hydroxine therapy (T4) in patients with mild thyroid failure, i.e. subclinical hypothyroidism.
The authors used a 13-item checklist of factors relating to internal and external validity, which covered study design, participant characteristics, treatment characteristics, and loss to follow-up. A score was calculated by assigning one point for each of 13 items assessed, and subscores were calculated for factors related to internal and external validity. Two reviewers evaluated the included studies for internal and external validity.
Data extraction
The authors do not state how many of the reviewers performed the data extraction.
Data were extracted for the categories: study identification and year of publication, study design, sample size, mean age within the study, selection criteria for patients, initial TSH (mU/L), final TSH (mU/L), and design score (0 to 13 points).
For each study without a control group, change was calculated as the mean difference between the final and pretreatment measurements for study participants. For each study with a control group, change was calculated as the difference between the two group mean differences.
Methods of synthesis
How were the studies combined? Weighted mean differences were calculated with 95% confidence intervals (CIs) using both random-effects and fixedeffect models.
Publication bias was assessed using common graphical and computational techniques.
How were differences between studies investigated?
In the fixed-effect analyses, homogeneity was assessed using the chi-squared statistic. The authors also used a weighted analysis of variance to stratify studies according to the individual terms on the study design (validity) checklist.
Weighted linear regression was used to evaluate the relationship between the baseline level of serum cholesterol and the change in serum cholesterol.
Results of the review
Thirteen studies were included with 247 participants. Three studies (23%) were RCTs with 81 participants.
Total cholesterol:
The mean decrease in the serum total cholesterol concentration (13 studies) was -0.20 mmol/L (-7.9 mg/dL; 95% CI: -0.09, -0.34) using the fixed-effect model, and -0.24 mmol/L (95% CI: -0.06, -0.42) using the random-effects model. The decline in serum total cholesterol was directly proportional to its baseline concentration. The test for heterogeneity suggested that these studies might be too dissimilar to combine.
Studies enrolling hypothyroid participants receiving suboptimal T4 doses (number of studies not stated) reported significantly larger decreases in serum total cholesterol after thyroid-stimulating hormone normalisation than those enrolling previously untreated individuals with mild thyroid failure: -0.44 mmol/L (-17 mg/dL; 95% CI: -0.18, -0.70) versus -0.14 mmol/L (-5.6 mg/dL; 95% CI: -0.01, -0.28); P=0.05.
LDL cholesterol:
The change in the serum LDL cholesterol concentration (9 studies) using a fixed-effect model was -0.26 mmol/L (-10 mg/dL; 95% CI: -0.12, -0.41). The results were more heterogeneous than would be expected by chance (P=0.02), but the reduction was similar using a random-effects model, -0.30 mmol/L (95% CI: -0.01, -0.54). The change in the serum HDL cholesterol concentration (10 studies) was an increase after therapy by 0.08 mmol/L (3.2 mg/dL; 95% CI: 0.04, 0.13) using the fixed-effect model; although statistically significant, the results were driven by one study. These results were also more heterogeneous than would be expected by chance (P<0.001). A similar reduction, which was statistically non significant, was obtained using a random-effects model, 0.02 mmol/L (95% CI: -0.09, 0.12).
HDL cholesterol:
Triglycerides:
The mean change in serum triglyceride concentration (12 studies) was -0.01 mmol/L (95% CI: -0.08, 0.06), which was not statistically significant.
The 3 RCTs were compared with the controlled studies, but the two groups were not statistically different. Division of studies into two groups according to the average age of participants, participant pre-treatment TSH level, participant final TSH level, overall study score, gender representation in the study, and use of free T4 testing for diagnosis, still did not separate the studies into statistically different groups.
No study fulfilled all 13 criteria relating to internal and external validity. Three to 8 criteria, with a median of 6 criteria, were met. Only 3 studies were randomised, all with placebo controls; 3 studies did not adequately characterise the selection of participants, and 7 of the studies neither discussed losses to follow-up nor gave sufficient information from which this could be determined.
